Buprenorphine Safely Manages 7-OH Withdrawal in Telehealth Case Series

Why it matters

As 7-OH products lose legal status nationwide, clinicians face a wave of patients in withdrawal with no established treatment protocol. This is the first published case series focused specifically on purified 7-OH products -- not standard kratom -- and it shows buprenorphine can be initiated safely even via telehealth.

The big picture

7-hydroxymitragynine binds mu-opioid receptors with up to 22 times the affinity of morphine, meaning withdrawal from concentrated 7-OH products can be severe and clinically distinct from standard kratom withdrawal. Buprenorphine has been used anecdotally for kratom dependence, but standardized clinical guidance has been absent. This retrospective chart review from a low-barrier telehealth addiction clinic is the most current clinical evidence addressing 7-OH specifically -- published just as federal scheduling takes effect and more patients are likely to seek treatment.

Key findings

• 9 patients with purified 7-OH product use disorders were treated at a telehealth addiction clinic between April and October 2025
• Mean patient age was 33.5 years; 7 of 9 were male
• Low-dose buprenorphine initiation was used in 6 cases; standard initiation in 3 cases
• 88.9% achieved successful initiation and stabilization with no precipitated withdrawal or adverse events
• Symptom improvement was reported in 8 of 9 cases at a median 6-week follow-up

What they say

The authors concluded: 'Buprenorphine initiation for problematic 7-OH use was feasible, well tolerated, and associated with symptom improvement, supporting development of pragmatic clinical approaches for this emerging substance use disorder.'

Bottom line

Buprenorphine works for 7-OH withdrawal -- and a low-dose telehealth protocol may be the most practical path as federal scheduling pushes users toward treatment.